About 8% of patients undergoing transcatheter aortic valve replacement (TAVR) develop new-onset atrial fibrillation. Development of new-onset atrial fibrillation is associated with a worse prognosis.

Patient selection: transcatheter aortic valve replacement, without atrial fibrillation


Risk factors for new-onset atrial fibrillation:

(1) vascular access other than transfemoral

(2) high Society of Thoracic Surgeons predicted risk of mortality (PROM) score

(3) female

(4) older age (with considerable overlap, using >= 85 years in the implementation)

(5) NYHA class III or IV heart failure

(6) severe COPD


Protective factor for new-onset atrial fibrillation:

(1) pacemaker


Risk factors for complications:

(1) discharge without anticoagulation


A patient who develops new-onset atrial fibrillation should have more aggressive management including the start of anticoagulation if possible.

To read more or access our algorithms and calculators, please log in or register.